Lung cancer trials in Serbia

In Serbia 8 Also abroad 2733

8 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 2/3Taking people
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Where
Belgrade, Kamenitz, Kragujevac, Užice
Age
18 years and over
People
626 worldwide
Run by
Mirati Therapeutics Inc.
See details and how to joinNCT04613596 · EU 2023-508922-83-00
Phase 1/2Taking people
A Platform Study in Non-Small Cell Lung Cancer (NSCLC)
Where
Belgrade, Kragujevac, Niš
Age
18 years and over
People
152 worldwide
Run by
AstraZeneca
See details and how to joinNCT06996782 · EU 2024-519786-22-01
Phase 2Taking people
A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer
Where
Belgrade, Kamenitz, Kragujevac, Niš
Age
18 years and over
People
180 worldwide
Run by
AbbVie
See details and how to joinNCT07155174 · EU 2024-517490-24-00
Phase 2Taking people
A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Where
Belgrade, Kamenitz, Kragujevac, Niš
Age
18 years and over
People
150 worldwide
Run by
AbbVie
See details and how to joinNCT06568939
Phase 3Taking people
BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01)
Where
Belgrade, Kragujevac, Novi Sad
Age
18 years and over
People
550 worldwide
Run by
SystImmune Inc.
See details and how to joinNCT07625644
Phase 2/3Taking people
A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
Where
Belgrade, Kamenitz, Kragujevac, Niš
Age
18 years and over
People
490 worldwide
Run by
AbbVie
See details and how to joinNCT07155187 · EU 2025-521124-29-00
Phase 3Taking people
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
Where
Belgrade, Kragujevac, Novi Sad
Age
18 years and over
People
780 worldwide
Run by
Summit Therapeutics
See details and how to joinNCT06767514 · EU 2024-518629-14-00
Phase 1/2Taking people
SNB-101 for Treatment of Extensive Stage Small Cell Lung Cancer
Where
Kamenitz
Age
18 years and over
People
55
Run by
SN BioScience
See details and how to joinNCT07391813